Radiation late effects in children treated for orbital rhabdomyosarcoma

Amedeo Fiorillo, Roberta Migliorati, Patrizia Vassallo, Gustavo Canale, Fausto Tranfa, Immacolata Fariello, Carolina De Chiara, Rosa D'Amore, Paolo Muto, Giulio Bonavolontà

Research output: Contribution to journalArticlepeer-review


Background and purpose: The experience resulting from large cooperative studies shows that correct radiation therapy at doses adequate to the tumor bulk are crucial for local control of rhabdomyosarcoma. The aim of the present study was to document the correlation between modalities and doses of radiotherapy and radiation side effects.Patients and methods: Between 1980 and 1997, ninteen patients affected by primary orbital rhabdomyosarcoma have been followed at the University Federico II of Naples. All but three patients, who received 45, 54 and 55 Gy respectively, have been treated by immediate radiation at the dose of 60 Gy, delivered in 2 Gy fractions, five times per week, by cobalt 60 megavoltage equipment. Combined chemotherapy using vincristine and vincristine plus dactinomycin on alternate weeks was also administered as part of induction therapy.Results: An overall survival rate of 94.7% was registered. In our patients the majority of radiation late effects were paid by orbit and ocular adnexa. Side effects to lens and ocular structures were fewer and of low grade.Conclusions: Radiation therapy is still esential for local control of orbital rhabdomyosarcoma, however radiation side effects have to be carefully considered together with the therapeutic goal to be obtained. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)143-148
Number of pages6
JournalRadiotherapy and Oncology
Issue number2
Publication statusPublished - Nov 1 1999


  • Late effects
  • Orbit
  • Radiotherapy
  • Rhabdomyosarcoma
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology


Dive into the research topics of 'Radiation late effects in children treated for orbital rhabdomyosarcoma'. Together they form a unique fingerprint.

Cite this